Advances in the Optimization of CAR-T-Cell-Based Therapeutic Approaches to Enhance Antitumor Efficacy in Glioblastoma Treatment

This is the authors' abstract. We don't add key points for this paper.

Chimeric antigen receptor (CAR)-T cell therapy is emerging as a promising immunotherapeutic modality for improving clinical outcomes in high-grade gliomas. Three recent studies have demonstrated the safety and feasibility of intracranial CAR-T cell administration in patients with glioblastoma (GBM), along with preliminary evidence of rapid but transient objective responses. These findings provide a rationale for further clinical investigation of this approach.